Ralliant (NYSE:RAL) Raised to Strong-Buy at Zacks Research

Ralliant (NYSE:RAL) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

RAL has been the subject of several other reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Wall Street Zen downgraded Ralliant from a “buy” rating to a “hold” rating in a report on Sunday. Truist Financial reaffirmed a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. TD Cowen lifted their target price on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 20th. Finally, Royal Bank Of Canada boosted their target price on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Ralliant Price Performance

Shares of NYSE:RAL opened at $71.93 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41. The business has a fifty day simple moving average of $59.71 and a 200 day simple moving average of $51.69. The firm has a market cap of $8.05 billion and a price-to-earnings ratio of -6.57.

Ralliant (NYSE:RAL) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million for the quarter. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, sell-side analysts predict that Ralliant will post 2.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RAL. Danske Bank A S bought a new position in shares of Ralliant in the 4th quarter valued at approximately $25,000. V Square Quantitative Management LLC bought a new stake in Ralliant during the fourth quarter worth approximately $26,000. Allworth Financial LP grew its holdings in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. Palisade Asset Management LLC acquired a new position in Ralliant during the third quarter valued at approximately $26,000. Finally, BOKF NA bought a new position in shares of Ralliant in the third quarter valued at approximately $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.